Treatment of Ionized Hypercalcemia in 12 Cats (2006–2008) Using PO‐Administered Alendronate

Journal of Veterinary Internal Medicine

B.T. Hardy⁵  J.F. de Brito Galvao³  T.A. Green⁴  S.R. Braudaway²  S.P. DiBartola¹  L. Lord¹ 

[1]Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, OH

[2]General Practioner, South Abington Twp, PA

[3]VCA Arboretum View Animal Hospital, Downers Grove, IL

[4]Small Animal Medicine and Surgery, St. George's University, Grenada, West Indies

[5]Santa Cruz Veterinary Hospital, Santa Cruz, CA

关键词: Bisphosphonate;    Feline;    Idiopathic hypercalcemia;    Ionized calcium;    Safety;   

DOI  :  10.1111/jvim.12507

来源: Wiley

【 摘 要 】

Abstract

Background

Long-term treatment of cats with ionized hypercalcemia using alendronate has not been evaluated.

Hypothesis/Objectives

Alendronate is well tolerated in treatment of ionized hypercalcemia in cats.

Animals

A total of 12 cats with ionized hypercalcemia.

Methods

Prospective study of 12 cats with ionized hypercalcemia of idiopathic origin was identified by telephone and email communication with a convenience sample of consulting veterinarians. Cats were treated with alendronate at a dose of 5–20 mg per feline PO q7d. Serum ionized calcium concentration (iCa) was measured before beginning treatment with alendronate, and after 1, 3, and 6 months of treatment. Alendronate dosage was adjusted according to iCa. Evaluation included physical examination, CBC, biochemistry profile, and diagnostic imaging. The owners and referring veterinarians were questioned about any observed adverse effects. The Wilcoxon matched-pairs signed rank test was used to compare baseline iCa to iCa at different time periods.

Results

Alendronate treatment resulted in a decrease in iCa in all 12 cats. The median percentage change in iCa was −13.2%, −15.9%, and −18.1% (range, −29.6 to +7.6; −30.5 to −1.9; −45.8 to +1.5%) at the 1, 3, and 6 month time points, respectively. Baseline iCa was significantly different from 1 month (P = .0042), 3 months (P = .0005), and 6 months (P = .0015). No adverse effects were reported for any of the cats.

Conclusions and Clinical Importance

Alendronate was well tolerated and decreased iCa in most cats for the 6-month period of observation.

【 授权许可】

CC BY-NC   
Copyright © 2015 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of American College of Veterinary Internal Medicine.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.